Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLX-110
- Development stage
- Preclinical
- Lead developer
- ClexBio
- Modality
- Cell Therapies
- Administration
- Surgical Implantation
01
Overview
CLX-110 is a bioengineered tissue therapeutic being developed by ClexBio for the treatment of late-stage liver disease. Utilizing the proprietary VivoSet technology platform, CLX-110 consists of fully vascularized hepatic tissue featuring cell-synthesized microvascular networks without the use of artificial materials. The therapy is designed to provide functional support or replacement of liver activity, serving as a bridge to transplant or recovery for patients with severe liver dysfunction. It incorporates hepatocytes and supporting cell types in a multicellular architecture to mimic native liver function and address the shortage of donor organs.
Beyond the preview
Go deeper on CLX-110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLX-110.